Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248088 | 1.00 | TSHR (0.39) | TSHRMAPTGAASMN1; SMN2LMNA | |
| SCHEMBL9446411 | 1.00 | TSHR (0.39) | TSHRMAPTGAASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL4246521 | 0.98 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL21805904 | 0.98 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL16010588 | 0.98 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2LMNA | |
| Succinic Acid SCHEMBL16009795 | 0.91 | SMN1; SMN2 (0.34) | TSHRMAPTGAASMN1; SMN2LMNA | |
| SCHEMBL25212730 | 0.88 | GAA (0.38) | TSHRMAPTGAASMN1; SMN2LMNA | |
| SCHEMBL799032 | 0.83 | CYP1A2 (0.43) | TSHRMAPTGAASMN1; SMN2LMNA | |
| SCHEMBL357615 | 0.83 | CYP1A2 (0.43) | TSHRMAPTGAASMN1; SMN2LMNA | |
| SCHEMBL799196 | 0.83 | CYP1A2 (0.43) | TSHRMAPTGAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205389-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | CHANG GUNG MEDICAL FOUND KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-07-08 | — | — | US | claimed |
| US-10953059-B2 | Methods and compositions for treating non-small cell lung cancer | CHANG GUNG MEDICAL FOUNDATION KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-03-23 | — | — | US | claimed |
| EP-3513809-A1 | MEDICINAL COMPOSITION | Kyowa Hakko Kirin Co., Ltd. (JP) | 2019-07-24 | — | — | EP | claimed |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2019-03-28 | — | — | US | claimed |
| EP-2964638-B1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2017-08-09 | — | — | EP | claimed |
| WO-2017042634-A2 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE | DEL MAR PHARMACEUTICALS (CA) | 2017-03-16 | — | — | WO | claimed |
| US-9375432-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2016-06-28 | — | — | US | claimed |
| EP-2964638-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | Astrazeneca AB (SE) | 2016-01-13 | — | — | EP | claimed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | claimed |
| WO-2014135876-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2014-09-12 | — | — | WO | claimed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | claimed |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | KYOWA KIRIN CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-04-11 | — | — | US | disclosed |
| US-11951103-B2 | Pharmaceutical composition | KYOWA KIRIN CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| WO-2024008929-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN COMBINATION WITH HGF-RECEPTOR INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-01-11 | — | — | WO | disclosed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014135876-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2014-09-12 | — | — | WO | disclosed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116926-A1 | HETEROAROMATIC COMPOUNDS | CYP1B1, CYP2D6, CYP1A1 | TSHR 3581/4885MAPT 2845/4885GAA 395/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | TSHR 2591/4885MAPT 3039/4885GAA 4598/4885 |
| US-20240207246-A1 | PHARMACEUTICAL COMPOSITION | EGFR, VEGFA, KDR | TSHR 412/4885MAPT 195/4885GAA 370/4885 |
| US-20190091195-A1 | USE OF DIANHYDROGALACTITOL AND DERIVATIVES THEREOF IN THE TREATMENT OF GLIOBLASTOMA, LUNG CANCER, AND OVARIAN CANCER | DDOST, DCLRE1A, OGG1 | TSHR 4615/4885MAPT 3406/4885GAA 2352/4885 |
| US-11951103-B2 | Pharmaceutical composition | EGFR, VEGFA, KDR | TSHR 412/4885MAPT 195/4885GAA 370/4885 |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ERBB2, ABL1 | TSHR 2349/4885MAPT 4146/4885GAA 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.